Innate adjuvant receptor Toll-like receptor 3 can promote breast cancer through cell surface

被引:14
|
作者
Bondhopadhyay, Banashree [1 ]
Moirangthem, Anuradha [1 ]
Basu, Anupam [1 ]
机构
[1] Univ Burdwan, Dept Zool, Mol Biol & Human Genet Lab, Burdwan 713104, W Bengal, India
关键词
Breast cancer; Adjuvant; E-cadherin; Poly (I:C); Toll-like receptor; TLR-3; Cell surface; RIG-I; ACTIVATION; APOPTOSIS; TUMOR; INDUCTION; ANTIBODY; GROWTH; TLR4;
D O I
10.1007/s13277-014-2737-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Toll-like receptor 3 has been targeted in different cancers for adjuvant therapy. The ligand-mediated effects of TLR-3 on cancer cells are discordant. In the present work, we have addressed the hypothesis possibility of cell membrane-bound action of TLR-3 in breast cancer to justify its pro-tumor effect. TLR-3 was stimulated by Poly (I:C) on the surface of human breast cancer cells MCF-7 and MDA-MB-231 for up to 72 h. To check the cell survival and growth, thiazol blue tetrazolium bromide (MTT) assay, apoptosis assay, and cell cycle analysis were carried out. For changes in the metastatic properties, in vitro colony formation assay, scratch-wound healing assay and adhesion assay were also done. Using real-time PCR and immunocytochemistry, expression of E-cadherin, was studied. To determine the affect of cytoplasmic stimulation, Poly (I:C) was delivered with lipid transfection reagent. The results of the aforesaid experiments showed that there was a gradual increase of cellular survivability, growth, and metastasis after the cell surface stimulation of TLR-3 with Poly (I:C). Interestingly, E-cadherin expression was increased both at transcriptional and translational level. On the other hand, when Poly (I:C) was delivered in the cytoplasm by lipid transfecting medium, the cells survivability was decreased. For the first time, in the present work, we are convincingly reporting the functional evidence that TLR-3 induces cell survivability and metastasis through cell surface. The present work may help for the proper understanding of the adjuvant therapy of breast cancer.
引用
收藏
页码:1261 / 1271
页数:11
相关论文
共 50 条
  • [31] Roles of Toll-Like Receptor 3 in Human Tumors
    Zheng, Xin
    Li, Song
    Yang, Hui
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [32] The Role of the Toll-like Receptor 2 and the cGAS-STING Pathways in Breast Cancer: Friends or Foes?
    Cossu, Chiara
    Di Lorenzo, Antonino
    Fiorilla, Irene
    Todesco, Alberto Maria
    Audrito, Valentina
    Conti, Laura
    Papadimitriou, Christos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
  • [33] Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade
    Chuang, Yu-Chen
    Tseng, Jen-Chih
    Huang, Li-Rung
    Huang, Chun-Ming
    Huang, Chi-Ying F.
    Chuang, Tsung-Hsien
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [34] miRNAs That Shape the Innate Immune System: Regulation through Toll-Like Receptor Signaling
    Curtis, Anne M.
    O'Neill, Luke A. J.
    INNATE IMMUNITY: RESISTANCE AND DISEASE-PROMOTING PRINCIPLES, 2013, 4 : 73 - +
  • [35] Toll-like receptor agonists in cancer therapy
    Adams, Sylvia
    IMMUNOTHERAPY, 2009, 1 (06) : 949 - 964
  • [36] Toll-like receptor 3 regulates cord blood-derived endothelial cell function in vitro and in vivo
    Grelier, Aurore
    Cras, Audrey
    Balitrand, Nicole
    Delmau, Catherine
    Lecourt, Severine
    Lepelletier, Yves
    Riesterer, Helene
    Freida, Delphine
    Lataillade, Jean-Jacques
    Lebousse-Kerdiles, Marie-Caroline
    Cuccini, Wendy
    de Latour, Regis Peffault
    Marolleau, Jean-Pierre
    Uzan, Georges
    Larghero, Jerome
    Vanneaux, Valerie
    ANGIOGENESIS, 2013, 16 (04) : 821 - 836
  • [37] Toll-Like Receptor 9 Agonists in Cancer
    Karapetyan, Lilit
    Luke, Jason J.
    Davar, Diwakar
    ONCOTARGETS AND THERAPY, 2020, 13 : 10039 - 10060
  • [38] Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy
    Matsumoto, Misako
    Takeda, Yohei
    Tatematsu, Megumi
    Seya, Tsukasa
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [39] Association between Toll-like receptor 3 polymorphisms and cancer risk: a meta-analysis
    Cheng, Daye
    Hao, Yiwen
    Zhou, Wenling
    Ma, Yiran
    TUMOR BIOLOGY, 2014, 35 (08) : 7837 - 7846
  • [40] Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood
    De Wit, D
    Tonon, S
    Olislagers, V
    Goriely, S
    Boutriaux, M
    Goldman, M
    Willems, F
    JOURNAL OF AUTOIMMUNITY, 2003, 21 (03) : 277 - 281